Treatment News : Hep C Protease Inhibitor Telaprevir Interacts With HIV Drugs - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 3, 2011

Hep C Protease Inhibitor Telaprevir Interacts With HIV Drugs

by Tim Horn

Vertex Pharmaceuticals’ hepatitis C virus (HCV) protease inhibitor telaprevir interacts to varying degrees with commonly used HIV antiretrovirals (ARVs), according to new data reported in two presentations at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), held February 28 through March 3 in Boston.

The HCV protease inhibitors currently in late-stage development and gearing up for approval—Vertex’s telaprevir and Merck’s boceprevir—hold tremendous potential for people living with chronic HCV infection, including people coinfected with HIV. Studies are still needed to fully understand the safety and efficacy of these agents, which will need to be combined with standard pegylated interferon and ribavirin therapy in coinfected patients. One early set of data involving telaprevir reported at CROI painted an encouraging picture—nonetheless, a potential overall concern is the way in which HCV protease inhibitors interact with HIV medications.

Specifically, the concern is that HCV protease inhibitors can cause blood levels of ARVs to become too high or too low, and vice versa. In turn, studies have been needed to look for such interactions, which can be used to determine whether or not some ARVs should be avoided while using HCV protease inhibitors or if dose adjustments are needed.

Several studies were presented at this year’s CROI. Reported here are the results of telaprevir-ARV interaction studies. Studies involving boceprevir and HIV medications will be reported separately. 

Minimal Interaction With Norvir (Ritonavir)

Results from Phase I study, presented by Varun Garg, PhD, of Vertex and his colleagues, involved HCV- and HIV-negative study volunteers receiving telaprevir—the standard dose of 750 milligrams (mg), three times daily, was used—in combination with twice-daily low doses (100 mg) of Norvir (ritonavir), an HIV protease inhibitor frequently used to boost the levels of other HIV protease inhibitors.

After 14 days of use of both drugs, no significant interactions between Norvir and telaprevir were noted. Unlike its affect on HIV protease inhibitors, Norvir did not boost blood concentrations of telaprevir.

While this is good news in terms of avoiding unwanted drug interactions, it is unlikely that Norvir boosting will allow for telaprevir dose reductions.

Some Interactions With Other ARVs

Rudolph van Heeswijk, PharmD, PhD, of Tibotec and his colleagues looked for interactions between telaprevir and a variety of HIV medications, including Norvir-boosted Reyataz (atazanavir), Norvir-boosted Prezista (darunavir), Norvir-boosted Lexiva (fosamprenavir), Kaletra (lopinavir/ritonavir), Sustiva (efavirenz) and Viread (tenofovir). Three studies, all involving HIV-negative and HCV-negative volunteers, were conducted.

Telaprevir slightly increased blood concentrations of Norvir-boosted Reyataz. Conversely, Novir-boosted Reyataz slightly reduced blood levels of telaprevir. However, this interaction was not considered to be clinically significant. In fact, Norvir-boosted Reyataz is one of the ARV regimens being studied in the HIV/HCV-coinfection study linked above.

An interaction between Sustiva and telaprevir was observed, but a higher dose of telaprevir (1,125 mg, every eight hours) largely offset the interaction. This higher dose of telaprevir, when combined with Sustiva, is also being studied in the HIV/HCV-coinfection study linked above.

Significant interactions were documented in study volunteers receiving telaprevir with Kaletra, Norvir-boosted Prezista and Norvir-boosted Lexiva. Based on these observations, van Heeswijk concluded, telaprevir treatment for HCV is not currently being evaluated for people taking these ARVs.

Search: telaprevir, interactions, Norvir, Prezista, Lexiva, Kaletra, Reyataz, Sustiva, hepatitis C, HCV, CROI


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.